Abstract
Novel iodinated cobalt bis(dicarbollide) conjugates with acridine were synthesized by the direct iodination of cobalt bis(dicarbollide) conjugates with acridine using crystalline iodine. The cytotoxicity of the new compounds against various human cell lines was evaluated. One of these compounds was found to be non-toxic to all cell types and was combined with polyvinylpyrrolidone to form a non-covalent complex in order to increase its water solubility. The BNCT experiment showed that pre-incubation with the new boron-containing complex followed by neutron irradiation reduces the survival of T98G glioblastoma cells to 25% and B16 melanoma cells to 17%. The biodistribution of the boron-containing compound 5-PVP was investigated in a B16F10 melanoma murine model. Maximum uptake in tumor and healthy tissues was observed 15 min after a single intravenous administration, and at 30 min post-injection the tumor/muscle ratio reached 5.4. This study lays the groundwork for further research on the development of methods for synthesizing acridine-based BNCT agents.